Skip to main content

Featured

Ukraine Marks Somber Anniversary as Zelenskyy Vows Resolve Amid Fractured Allied Support

Ukrainians pay tribute to victims of the Russian invasion, on the day marking the fourth anniversary of the full-scale Russian invasion. As Ukraine enters another year of full‑scale war, President Volodymyr Zelenskyy used the anniversary to deliver a message of defiance and endurance. Speaking to the nation, he emphasized that Ukraine’s determination to resist Russia has not weakened, even as the conflict grinds on with no clear end in sight. Zelenskyy highlighted the sacrifices made by civilians and soldiers alike, framing Ukraine’s struggle as a fight for national survival and democratic values. His remarks came at a moment when international unity — once a defining feature of the early months of the invasion — shows signs of strain. Several of Ukraine’s key partners remain committed to providing military and financial support, but political divisions, shifting priorities, and domestic pressures in some allied countries have complicated efforts to maintain a cohesive front. Debates...
Post a Comment
Read more

article

Labels

Alzheimer’s Drug Donanemab Receives FDA Advisers’ Endorsement for Slowing Disease Progression

 

A significant milestone has been reached in the fight against Alzheimer’s disease. Eli Lilly’s closely watched Alzheimer’s drug, donanemab, has won the unanimous backing of federal health advisers. The drug is specifically intended for people with mild dementia caused by this brain-robbing disease.

The decision by the Food and Drug Administration (FDA) advisers comes after careful consideration of the drug’s benefits and risks. Donanemab has demonstrated the ability to modestly slow cognitive decline and memory problems associated with Alzheimer’s. Although it’s not a cure, this endorsement represents a promising step forward in managing the disease.

Here are the key points:

  1. Effectiveness: Donanemab has shown effectiveness in slowing cognitive decline. Patients who received monthly intravenous infusions of the drug declined about 35% more slowly than those who received a placebo.
  2. Risk Assessment: The FDA panel weighed the risks, including side effects like brain swelling and bleeding, which will need monitoring. Despite these risks, the panel concluded that the drug’s benefits outweighed them.
  3. Tau Protein Screening: Unlike previous concerns about tau protein screening, most panelists believed there was enough evidence to prescribe the drug broadly without requiring such screening.
  4. FDA Decision: The FDA will make the final decision on approval later this year. If approved, donanemab would become only the second Alzheimer’s drug in the U.S. shown to convincingly slow cognitive decline.

This endorsement brings hope to individuals and families affected by Alzheimer’s, and we eagerly await the FDA’s final decision. Stay tuned for further updates on this groundbreaking development! 

Labels:

Comments

Post a Comment